Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$419.38
+1.0%		$372.05
$269.77
▼
$421.79
$224.48B0.412.71 million shs2.88 million shs
Biogen Inc. stock logo
BIIB
Biogen
$209.15
-0.3%		$204.09
$131.52
▼
$219.72
$31.00B0.17981,864 shs617,104 shs
Incyte Corporation stock logo
INCY
Incyte
$123.50
+2.8%		$114.53
$81.09
▼
$132.60
$24.36B0.761.83 million shs2.04 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,184.44
+0.4%		$1,171.52
$685.15
▼
$1,249.45
$1.11T0.512.67 million shs1.81 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.04%+13.36%+28.00%+40.05%
Biogen Inc. stock logo
BIIB
Biogen
0.00%+0.91%+1.86%+9.34%+51.39%
Incyte Corporation stock logo
INCY
Incyte
0.00%-0.33%+2.48%+26.23%+38.24%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-0.38%+0.36%+19.57%+68.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$419.38
+1.0%		$372.05
$269.77
▼
$421.79
$224.48B0.412.71 million shs2.88 million shs
Biogen Inc. stock logo
BIIB
Biogen
$209.15
-0.3%		$204.09
$131.52
▼
$219.72
$31.00B0.17981,864 shs617,104 shs
Incyte Corporation stock logo
INCY
Incyte
$123.50
+2.8%		$114.53
$81.09
▼
$132.60
$24.36B0.761.83 million shs2.04 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,184.44
+0.4%		$1,171.52
$685.15
▼
$1,249.45
$1.11T0.512.67 million shs1.81 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.04%+13.36%+28.00%+40.05%
Biogen Inc. stock logo
BIIB
Biogen
0.00%+0.91%+1.86%+9.34%+51.39%
Incyte Corporation stock logo
INCY
Incyte
0.00%-0.33%+2.48%+26.23%+38.24%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-0.38%+0.36%+19.57%+68.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$372.39-11.20% Downside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$227.078.57% Upside
Incyte Corporation stock logo
INCY
Incyte
2.43
Hold$121.65-1.50% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,292.189.10% Upside

Current Analyst Ratings Breakdown

Latest LLY, AMGN, BIIB, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Incyte Corporation stock logo
INCY
Incyte
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$110.00 ➝ $130.00
8/14/2026
Amgen Inc. stock logo
AMGN
Amgen
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$360.00 ➝ $380.00
8/13/2026
Incyte Corporation stock logo
INCY
Incyte
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform$104.00
8/13/2026
Biogen Inc. stock logo
BIIB
Biogen
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/12/2026
Biogen Inc. stock logo
BIIB
Biogen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
8/11/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/10/2026
Amgen Inc. stock logo
AMGN
Amgen
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$343.00 ➝ $388.00
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$1,376.00
8/7/2026
Amgen Inc. stock logo
AMGN
Amgen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$345.00 ➝ $405.00
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,370.00 ➝ $1,376.00
8/6/2026
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B6.17$34.15 per share12.28$16.08 per share26.08
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.12$22.56 per share9.27$124.45 per share1.68
Incyte Corporation stock logo
INCY
Incyte
$5.14B4.87$6.35 per share19.44$26.32 per share4.69
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B17.11$25.23 per share46.95$28.07 per share42.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0926.0617.303.8622.95%124.14%13.18%11/3/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6537.0212.766.488.32%11.18%6.88%10/29/2026 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$1.29B$7.8515.7315.573.7727.71%29.93%22.88%10/27/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8039.7525.821.3933.53%97.83%23.23%10/29/2026 (Estimated)

Latest LLY, AMGN, BIIB, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
7/28/2026Q2 2026
Incyte Corporation stock logo
INCY
Incyte
$2.15$3.09+$0.94$2.81$1.50 billion$1.67 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.40%+8.27%62.65%14 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.58%+15.18%23.22%11 Years

Latest LLY, AMGN, BIIB, and INCY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.6%8/21/20268/21/20269/11/2026
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.59%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Incyte Corporation stock logo
INCY
Incyte
N/A
4.59
4.51
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Incyte Corporation stock logo
INCY
Incyte
16.20%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844202.70 million169.86 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable

Recent News About These Companies

Eli Lilly (NYSE:LLY) Lifts Guidance on Retatrutide Trial Wins
 |  kalkinemedia.comK
Jim Cramer Says One Group of Stocks is ‘So Hated’ Right Now. Is it Time to Buy?
 |  247wallst.comhttps://247wallst.com/investing/2026/08/17/jim-cramer-says-one-group-of-stocks-is-so-hated-right-now-is-it-time-to-buy/
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/omniab-jumps-18-lilly-deal-204708905.html
Jim Cramer Says One Group of Stocks is ‘So Hated' Right Now. Is it Time to Buy?
August 17 at 3:47 PM  |  247wallst.comhttps://247wallst.com/investing/2026/08/17/jim-cramer-says-one-group-of-stocks-is-so-hated-right-now-is-it-time-to-buy/?utm_source=snapi
Pharmaceutical Stocks To Add to Your Watchlist - August 17th
August 17 at 2:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/pharmaceutical-stocks-to-add-to-your-watchlist-august-17th-2026-08-17/
Can Eli Lilly (LLY) Stay Undervalued If Growth Keeps Delivering?
August 17 at 1:48 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-stay-undervalued-151537377.html
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
August 17 at 12:12 PM  |  zacks.comhttps://www.zacks.com/stock/news/2975753/lly-up-around-6-post-robust-q2-results-buy-sell-or-hold-the-stock?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2975753
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
August 17 at 10:51 AM  |  zacks.comhttps://www.zacks.com/stock/news/2975648/why-eli-lilly-lly-is-a-top-momentum-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_momentum_score-2975648
Why Is Omniab Stock Rallying After Eli Lilly Deal?
August 17 at 9:31 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61245655/why-is-omniab-stock-rallying-after-eli-lilly-deal
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer
August 17 at 8:48 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zacks-industry-outlook-highlights-eli-094600001.html
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
August 17 at 8:48 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/omniab-announces-global-collaboration-license-100100483.html
OmniAb boosts 2026 cash outlook following Eli Lilly deal
August 17 at 7:31 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4633752-omniab-boosts-2026-cash-outlook-following-eli-lilly-deal?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
Willis Investment Counsel Purchases 3,240 Shares of Eli Lilly and Company $LLY
August 17 at 6:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-willis-investment-counsel-purchases-3240-shares-of-eli-lilly-and-company-lly-2026-08-17/
2,260 Shares in Eli Lilly and Company $LLY Acquired by Meridian Management Co.
August 17 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2260-shares-in-eli-lilly-and-company-lly-acquired-by-meridian-management-co-2026-08-17/
Heritage Investors Management Corp Grows Stake in Eli Lilly and Company $LLY
August 17 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-heritage-investors-management-corp-grows-stake-in-eli-lilly-and-company-lly-2026-08-17/
TD Asset Management Inc Decreases Stock Position in Eli Lilly and Company $LLY
August 17 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-decreases-stock-position-in-eli-lilly-and-company-lly-2026-08-17/
Eli Lilly and Company $LLY Shares Acquired by Strive Financial Group LLC
August 17 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-shares-acquired-by-strive-financial-group-llc-2026-08-17/
Eli Lilly and Company $LLY is Suncoast Equity Management's 5th Largest Position
August 17 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-is-suncoast-equity-managements-5th-largest-position-2026-08-17/
Qsemble Capital Management LP Trims Stock Position in Eli Lilly and Company $LLY
August 17 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-qsemble-capital-management-lp-trims-stock-position-in-eli-lilly-and-company-lly-2026-08-17/
Eli Lilly and Company $LLY Position Lowered by Chilton Capital Management LLC
August 17 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-position-lowered-by-chilton-capital-management-llc-2026-08-17/
Gateway Wealth Partners LLC Has $3.15 Million Stock Holdings in Eli Lilly and Company $LLY
August 17 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-gateway-wealth-partners-llc-has-315-million-stock-holdings-in-eli-lilly-and-company-lly-2026-08-17/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laptop displaying stock price and bar charts on a desk, surrounded by icons representing tech, banking, healthcare, and retail sectors.
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
By Jessica Mitacek | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
Western Digital (WD) logo rendered in 3D on a circuit board with blurred server racks in the background.
Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
By Sam Quirke | July 28, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
An upward-trending arrow drawn in beach sand, symbolizing rising stock prices, with beachgoers in the background.
3 Stocks Taking Very Different Routes Through the Summer Rally
By Nathan Reiff | August 5, 2026
Amgen stock logo

Amgen NASDAQ:AMGN

$419.38 +4.17 (+1.00%)
As of 04:00 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$209.15 -0.68 (-0.32%)
As of 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte stock logo

Incyte NASDAQ:INCY

$123.50 +3.34 (+2.78%)
As of 04:00 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,184.44 +4.28 (+0.36%)
As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas